SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
Status:
Terminated
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to
prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia
(BPD), in premature infants who have required continued intubation and received surfactants
for the prevention or treatment of respiratory distress syndrome (RDS).